ATE76747T1 - Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. - Google Patents

Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Info

Publication number: ATE76747T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; methyl ester; preparation; compositions containing; therapeutic uses
Prior art date: 1986-06-10

Application number

AT87107979T

Other languages

English (en)

Inventor

Paolo Chiesi

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-06-10

Filing date

1987-06-02

Publication date

1992-06-15

1986-06-10 Priority claimed from IT20737/86A external-priority patent/IT1190342B/it

1987-01-30 Priority claimed from IT19221/87A external-priority patent/IT1203321B/it

1987-06-02 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

1992-06-15 Application granted granted Critical

1992-06-15 Publication of ATE76747T1 publication Critical patent/ATE76747T1/de

Links

229960001794 melevodopa Drugs 0.000 title abstract 2
XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 title 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
230000001078 anti-cholinergic effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003291 dopaminomimetic effect Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000002899 monoamine oxidase inhibitor Substances 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT87107979T 1986-06-10 1987-06-02 Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. ATE76747T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IT20737/86A IT1190342B (it)	1986-06-10	1986-06-10	Composizioni farmaceutiche contenenti levodopa metil estere,loro procedimento di preparazione e relative applicazioni terapeutiche
IT19221/87A IT1203321B (it)	1987-01-30	1987-01-30	Composizioni farmaceutiche contenenti levodora metil estere,loro prodecimento di preparazione e relative applicazioni terapeutiche
EP87107979A EP0252290B1 (de)	1986-06-10	1987-06-02	Levodopa-methyl-ester enthaltende pharmazeutische Zusammensetzungen, ihre Herstellung und therapeutische Verwendungen

Publications (1)

Publication Number	Publication Date
ATE76747T1 true ATE76747T1 (de)	1992-06-15

Family

ID=26327098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT87107979T ATE76747T1 (de)	1986-06-10	1987-06-02	Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Country Status (13)

Country	Link
US (2)	US4826875A (de)
EP (1)	EP0252290B1 (de)
JP (1)	JP2572768B2 (de)
KR (2)	KR880000092A (de)
AT (1)	ATE76747T1 (de)
AU (1)	AU605154B2 (de)
CA (1)	CA1303509C (de)
DE (2)	DE252290T1 (de)
ES (1)	ES2042520T3 (de)
GR (1)	GR880300058T1 (de)
HU (1)	HUT43952A (de)
NZ (1)	NZ220631A (de)
PT (1)	PT85055B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4983400A (en) *	1986-06-16	1991-01-08	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
IL92952A (en) *	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en)	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
SE9203594D0 (sv) *	1992-11-30	1992-11-30	Christer Nystroem	Laekemedel i dispersa system
US5607969A (en) *	1992-12-24	1997-03-04	Yissum Research Development Company Of The Hebrew University Of Jerusalem	L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) *	1992-12-24	1994-10-11	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Process for preparing ethyl ester of L-DOPA
DE4325435A1 (de) *	1993-07-29	1995-02-02	Basf Ag	Neue Wirkstoffkombination
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US20050106241A1 (en) *	1995-02-03	2005-05-19	Brewer Francesca M.	Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
ATE241346T1 (de) *	1995-03-02	2003-06-15	Scherer Technologies Inc R P	Arzneimittel enthaltend monoaminooxidase-b-hemmer
US6316022B1 (en)	1995-06-07	2001-11-13	Noven Pharmaceuticals, Inc.	Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
CA2223588C (en)	1995-06-07	2004-01-06	Noven Pharmaceuticals, Inc.	Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
JPH11504944A (ja) *	1995-11-06	1999-05-11	サマーセット・ファーマシューティカルズ・インコーポレイテッド	セレギリンの舌下およびバッカル投与
IL119417A (en) *	1996-10-13	2003-02-12	Moshe Kushnir	Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
DE69738275T2 (de)	1996-12-18	2008-08-28	Teva Pharmaceutical Industries Ltd.	Aminoindanderivate
US20040151768A1 (en) *	1997-07-23	2004-08-05	Chiesi Farmaceutici S.P.A.	Pharmaceutical compositions containing an effervescent acid-base couple
IT1293764B1 (it) *	1997-07-23	1999-03-10	Chiesi Farma Spa	Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
DK1063981T3 (da) *	1998-03-16	2002-10-14	Somerset Pharmaceuticals Inc	Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
NZ512027A (en)	1998-11-10	2004-04-30	Teva Pharma	Dispersible compositions containing L-dopa ethyl ester
WO2000027801A1 (en)	1998-11-10	2000-05-18	Teva Pharmaceutical Industries, Ltd.	Process for manufacture of l-dopa ethyl ester
US6506378B1 (en)	1998-12-16	2003-01-14	Arch Development Corporation	Vesicular monoamine transporter gene therapy in Parkinson's disease
US6737547B1 (en)	1998-12-31	2004-05-18	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using N-acyl-1H-aminoindenes
US20020151526A1 (en) *	2000-10-06	2002-10-17	Gallop Mark A.	Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
US20040010038A1 (en) *	2002-02-27	2004-01-15	Eran Blaugrund	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US8338420B1 (en)	2002-12-04	2012-12-25	Mitsubishi Tanabe Pharma Corporation	Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US7101912B2 (en)	2002-12-06	2006-09-05	Xenoport, Inc.	Carbidopa prodrugs and derivatives, and compositions and uses thereof
DE10261807A1 (de) *	2002-12-19	2004-07-01	Turicum Drug Development Ag	Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
AR044007A1 (es)	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
JP2006524708A (ja) *	2003-04-25	2006-11-02	インディヴァスファーマシューティカルズ，インコーポレーテッド	塩化トロスピウムの投与により連続睡眠を促進するための方法
US8815950B2 (en)	2003-08-29	2014-08-26	Janssen Biotech, Inc.	Pharmaceutical compositions and method of using levodopa and carbidopa
DE602004031134D1 (de) *	2003-08-29	2011-03-03	Transform Pharmaceuticals Inc	Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
KR20080109101A (ko) *	2003-10-20	2008-12-16	테바 파마슈티컬 인더스트리즈 리미티드	레보도파의 지속적 효과를 위한 조성물 및 제형
US7576073B2 (en) *	2004-05-28	2009-08-18	UNIVERSITé LAVAL	Combined therapy for the treatment of parkinson's disease
WO2005121070A1 (en) *	2004-06-04	2005-12-22	Xenoport, Inc.	Levodopa prodrugs, and compositions and uses thereof
PT1751087E (pt) *	2004-06-04	2012-09-10	Xenoport Inc	Derivados de levodopa e as suas composições e utilizações
SE0401842D0 (sv)	2004-07-12	2004-07-12	Dizlin Medical Design Ab	Infusion and injection solution of levodopa
US20060173074A1 (en)	2004-11-10	2006-08-03	Juha Ellmen	Treatment of restless legs syndrome
CA2613631A1 (en) *	2005-06-23	2007-01-04	Spherics, Inc.	Improved dosage forms for movement disorder treatment
WO2007011907A2 (en) *	2005-07-19	2007-01-25	University Of Rochester	Alpha-synuclein antibodies and methods related thereto
US7563821B2 (en) *	2005-12-05	2009-07-21	Xenoport, Inc.	Levodopa prodrug mesylate, compositions thereof, and uses thereof
AU2006326642B2 (en) *	2005-12-09	2012-05-03	Technion Research And Development Foundation Ltd.	Use of low-dose ladostigil for neuroprotection
CA2642593C (en) *	2006-02-17	2014-11-04	Birds Pharma Gmbh Berolina Innovative Research & Development Services	Deuterated catecholamine derivatives and medicaments comprising said compounds
TW200744576A (en) *	2006-02-24	2007-12-16	Teva Pharma	Propargylated aminoindans, processes for preparation, and uses thereof
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
CA2673336A1 (en)	2006-12-21	2008-06-26	Xenoport, Inc.	Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079387A1 (en) *	2006-12-21	2008-07-03	Xenoport, Inc.	Catechol protected levodopa diester prodrugs, compositions, and methods of use
AU2007338631A1 (en) *	2006-12-22	2008-07-03	Combinatorx, Incorporated	Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008095297A1 (en)	2007-02-06	2008-08-14	Origin Biomed Inc.	Composition comprising terpene compounds and methods for inhibiting nerve transmission
US20090143388A1 (en) *	2007-08-29	2009-06-04	Mohanakumar Kochupurackal Para	Treatment of brain disorders
CN101283965B (zh) *	2007-10-26	2010-06-16	南京长澳医药科技有限公司	一种含左旋多巴甲酯的制剂及制备方法
CN101910113A (zh)	2007-12-28	2010-12-08	怡百克制药公司	左旋多巴控释制剂及其用途
CA2732784C (en)	2008-08-13	2018-09-18	Neuroquest Inc.	Compositions comprising terpene compounds for treating negative sensory phenomena
US9290445B2 (en) *	2008-10-20	2016-03-22	Xenoport, Inc.	Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) *	2008-10-20	2013-03-19	Xenoport, Inc.	Levodopa prodrug mesylate hydrate
US8286311B2 (en)	2008-10-31	2012-10-16	Jisook Paik	Buckle
US20120128654A1 (en) *	2009-04-23	2012-05-24	University Of Cincinnati	Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma
PL2432454T3 (pl)	2009-05-19	2017-10-31	Neuroderm Ltd	Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
WO2011056240A2 (en)	2009-11-09	2011-05-12	Xenoport, Inc.	Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
KR101196354B1 (ko)	2010-09-03	2012-11-01	서유헌	퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
PT2640358T (pt)	2010-11-15	2018-02-23	Neuroderm Ltd	Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
WO2012079072A2 (en) *	2010-12-10	2012-06-14	Synagile Corporation	Subcutaneously infusible levodopa prodrug compositions and methods of infusion
NZ703341A (en)	2012-06-05	2016-11-25	Neuroderm Ltd	Compositions comprising apomorphine and organic acids and uses thereof
WO2014164730A2 (en)	2013-03-12	2014-10-09	The Board Of Trustees Of The Leland Stanford Junior University	Modulation of cellular dna repair activity to intercept malignancy
JP6456909B2 (ja)	2013-03-15	2019-01-23	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｌｘｒ調節因子
CN105209039B (zh)	2013-03-15	2018-06-22	百时美施贵宝公司	Lxr调节剂
WO2015027431A1 (en)	2013-08-29	2015-03-05	Merck Sharp & Dohme Corp.	2,2-difluorodioxolo a2a receptor antagonists
CN105658211A (zh)	2013-10-07	2016-06-08	怡百克制药公司	左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10987313B2 (en)	2013-10-07	2021-04-27	Impax Laboratories, Llc	Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
DK3116475T3 (da)	2014-03-13	2020-12-07	Neuroderm Ltd	Dopa-decarboxylasehæmmersammensætninger
US10258585B2 (en)	2014-03-13	2019-04-16	Neuroderm, Ltd.	DOPA decarboxylase inhibitor compositions
CN113197851A (zh)	2015-05-06	2021-08-03	辛纳吉勒公司	包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
WO2019166322A1 (en)	2018-03-02	2019-09-06	Chiesi Farmaceutici S.P.A.	A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
US11331293B1 (en)	2020-11-17	2022-05-17	Neuroderm, Ltd.	Method for treatment of Parkinson's disease
US11844754B2 (en)	2020-11-17	2023-12-19	Neuroderm, Ltd.	Methods for treatment of Parkinson's disease
US11213502B1 (en)	2020-11-17	2022-01-04	Neuroderm, Ltd.	Method for treatment of parkinson's disease
KR20230124622A (ko)	2020-12-22	2023-08-25	암닐 파마슈티컬스 엘엘씨	레보도파 투여 요법
US11986449B2 (en)	2020-12-22	2024-05-21	Amneal Pharmaceuticals Llc	Levodopa dosing regimen
US12161612B2 (en)	2023-04-14	2024-12-10	Neuroderm, Ltd.	Methods and compositions for reducing symptoms of Parkinson's disease
WO2025075499A1 (en)	2023-10-02	2025-04-10	Universiteit Van Amsterdam	Reducing dopamine feed-back inhibition in dopaminergic cells by tadalafil.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3787581A (en)	1970-03-24	1974-01-22	M Sandler	Pharmaceutical compositions and methods of treatment
JPS5157813A (en) *	1974-11-14	1976-05-20	Sankyo Co	Ll dooba mataha sonojudotaiseizaino seiho
US4663349A (en) *	1985-12-30	1987-05-05	Merck & Co., Inc.	Rectally absorbable form of L-dopa

1987
- 1987-06-02 DE DE198787107979T patent/DE252290T1/de active Pending
- 1987-06-02 EP EP87107979A patent/EP0252290B1/de not_active Expired - Lifetime
- 1987-06-02 AT AT87107979T patent/ATE76747T1/de not_active IP Right Cessation
- 1987-06-02 DE DE8787107979T patent/DE3779500T2/de not_active Expired - Lifetime
- 1987-06-02 ES ES87107979T patent/ES2042520T3/es not_active Expired - Lifetime
- 1987-06-08 AU AU74053/87A patent/AU605154B2/en not_active Expired
- 1987-06-09 PT PT85055A patent/PT85055B/pt not_active IP Right Cessation
- 1987-06-09 CA CA000539220A patent/CA1303509C/en not_active Expired - Lifetime
- 1987-06-09 HU HU872628A patent/HUT43952A/hu unknown
- 1987-06-09 KR KR870005806A patent/KR880000092A/ko not_active Withdrawn
- 1987-06-09 JP JP62143959A patent/JP2572768B2/ja not_active Expired - Lifetime
- 1987-06-09 NZ NZ220631A patent/NZ220631A/en unknown
- 1987-07-21 KR KR1019870007874A patent/KR950002150B1/ko not_active Expired - Lifetime
- 1987-11-20 US US07/123,118 patent/US4826875A/en not_active Expired - Lifetime
1988
- 1988-05-20 GR GR88300058T patent/GR880300058T1/el unknown
1989
- 1989-06-30 US US07/374,273 patent/US5017607A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE3779500T2 (de)	1993-01-21
CA1303509C (en)	1992-06-16
HUT43952A (en)	1988-01-28
US4826875A (en)	1989-05-02
DE252290T1 (de)	1988-06-09
AU605154B2 (en)	1991-01-10
GR880300058T1 (en)	1988-10-18
PT85055B (pt)	1994-10-31
US5017607A (en)	1991-05-21
EP0252290A2 (de)	1988-01-13
KR890001533A (ko)	1989-03-27
JP2572768B2 (ja)	1997-01-16
PT85055A (pt)	1988-07-01
JPS6327428A (ja)	1988-02-05
EP0252290A3 (en)	1990-01-24
DE3779500D1 (de)	1992-07-09
KR950002150B1 (ko)	1995-03-14
KR880000092A (ko)	1988-03-23
NZ220631A (en)	1990-12-21
ES2042520T3 (es)	1993-12-16
EP0252290B1 (de)	1992-06-03
AU7405387A (en)	1987-12-17

Legal Events

Date	Code	Title	Description
1992-12-15	UEP	Publication of translation of european patent specification
2007-09-15	EELA	Cancelled due to lapse of time

Publication	Publication Date	Title
ATE76747T1 (de)	1992-06-15	Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DE3686483D1 (de)	1992-09-24	Arzneimittel.
NO166448C (no)	1991-07-24	Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
DE69223914D1 (de)	1998-02-12	4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate
NO904986L (no)	1991-05-21	Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
PT615754E (pt)	2002-11-29	Formas solidas de administracao oral de libertacao controlada flupertina
MX9203417A (es)	1992-07-01	Compuestos de diarilo antiateroescleroticos.
FR2711140B1 (fr)	1996-01-05	1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
DK0412554T3 (da)	1994-12-12	Sustained-release-præparat til administration i hjernen
SE8404065D0 (sv)	1984-08-10	Novel biologically active compounds
DK0629400T3 (da)	2000-02-14	Idebenon-holdige præparater til behandling af Alzheimer's syge
NO900697D0 (no)	1990-02-13	Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater.
DE69835461D1 (de)	2006-09-14	Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
FR2707638B1 (fr)	1995-08-18	Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
HUP9802897A3 (en)	2001-08-28	Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
ATE5256T1 (de)	1983-11-15	Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
KR900009029A (ko)	1990-07-02	가축병 치료용 약물을 투여하는 장치
NO172491C (no)	1993-07-28	Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater
SE8802323D0 (sv)	1988-06-21	8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
TH14574A (th)	1994-08-26	สารผสมทางเภสัชกรรม
UA30143A (uk)	2000-11-15	Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
NO164651C (no)	1990-10-31	Analogifremgangsmaate for fremstilling av terapeutisk aktive aminofenol-derivater.
NO168106C (no)	1992-01-15	Analogifremgangsmaate for fremstilling av terapeutisk aktive estere av hexahydro-8-hydroxy-2,6-methano-2h-kinolizin-3(4h)-on
IT1238210B (it)	1993-07-12	Esteri del cefamandolo nafato, procedimento per la loro preparazione erelative composizioni farmaceutiche.
IT8720229A0 (it)	1987-04-23	Composizioni farmaceutiche adattivita' spasmolitica contenente come principio attio idanpramina